Eribulin mesylate

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory Rhabdomyosarcoma

Conditions

Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma

Trial Timeline

Apr 17, 2018 → Jan 21, 2022

NCT ID

NCT03441360

About Eribulin mesylate

Eribulin mesylate is a phase 2 stage product being developed by Eisai for Relapsed/Refractory Rhabdomyosarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03441360. Target conditions include Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma.

What happened to similar drugs?

0 of 10 similar drugs in Relapsed/Refractory Rhabdomyosarcoma were approved

Approved (0) Terminated (1) Active (9)

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3

🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3

❌Blinatumomab + Standard of Care ChemotherapyAmgenPhase 3

🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3

🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + BendamustineGilead SciencesPhase 3

🔄Odronextamab + Lenalidomide + RituximabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03441360	Phase 2	Completed	Apr 17, 2018	Jan 21, 2022	Relapsed/Refractory Rhabdomyosarcoma
NCT03583944	Approved	Completed	Mar 28, 2018	Jun 28, 2019	Breast Neoplasms
NCT03361436	Phase 1	Active	Mar 19, 2018	Apr 14, 2033	Liposarcoma
NCT03437083	Pre-clinical	Completed	Jan 25, 2018	Jun 30, 2018	Locally Advanced or Metastatic Breast Cancer
NCT03058406	Pre-clinical	Completed	Mar 1, 2016	Nov 4, 2018	Sarcoma, Soft Tissue
NCT02481050	Phase 2	Completed	Jun 16, 2015	Sep 5, 2017	Breast Cancer
NCT02338037	Phase 1	Completed	May 19, 2015	Mar 15, 2024	Metastatic Malignant Neoplasm in the Adult Brain
NCT02171260	Phase 1	Completed	Jul 31, 2014	Jan 28, 2016	Pediatrics
NCT03245112	Pre-clinical	UNKNOWN	Mar 3, 2014	Dec 31, 2017	Metastatic Breast Cancer
NCT01961544	Approved	Completed	Jun 1, 2013	Jul 1, 2015	Breast Neoplasms
NCT01458249	Phase 2	Completed	Nov 1, 2011	Feb 1, 2016	Soft Tissue Sarcoma
NCT01463891	Pre-clinical	Completed	Jul 19, 2011	Nov 27, 2013	Inoperable or Recurrent Breast Cancer
NCT01328249	Phase 2	Completed	Mar 3, 2011	Oct 19, 2017	HER2-normal
NCT01240421	Pre-clinical	Completed	Mar 1, 2011	Nov 1, 2014	Metastatic Breast Cancer
NCT01268150	Phase 2	Completed	Feb 1, 2011	Aug 1, 2013	Locally Recurrent
NCT01269346	Phase 2	Completed	Dec 1, 2010	May 1, 2016	Breast Cancer
NCT01142661	Pre-clinical	Completed	Aug 1, 2010	—	Breast Cancer
NCT01106248	Phase 1	Completed	Mar 1, 2009	—	Advanced Solid Tumor
NCT00965523	Phase 2	Completed	Jan 1, 2008	Jan 1, 2011	Breast Cancer

Competing Products

20 competing products in Relapsed/Refractory Rhabdomyosarcoma

See all competitors

Product	Company	Stage	Hype Score
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-2416	Moderna	Phase 2	0
agenT-797	MiNK Therapeutics	Phase 1	19
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	47
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	36
ISB 1342	Glenmark Pharmaceuticals	Phase 1	29
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide	Jiangsu Hengrui Medicine	Phase 3	47
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	39
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	42
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	40
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	29
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	32
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
AZD4573	AstraZeneca	Phase 2	35
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	26
Administration of AZD6738	AstraZeneca	Phase 1	29